SunRock Biopharma

SunRock Biopharma

Description

SunRock Biopharma is dedicated to developing therapeutic antibodies to fight cancer. Currently SunRock Biopharma’s efforts are focused on two processes:

• The development of therapeutic anti-CCR9 antibodies, a novel therapeutic target expressed in Acute T Lymphoblastic Leukemia.
• The development of therapeutic anti-HER3 antibodies, a central node in the regulation of many cancers, including triple-negative breast cancer and colorectal cancer. Against this target SunRock also develops biospecific anti-HER3/anti-EGFR antibodies in several different formats.

Most important R+D+i projects

Project CCR9 :

• CCR9
• Therapeutic anti-CCR9 antibodies

Project HER3:

• HER3
• Therapeutic anti-HER3 antibodies

Innovation Plan (INNOVAPEME Programme)

Contact

Phone: +34 881 975 523

Email: info@sunrockbiopharma.com